Prevalence of Primary Aldosteronism in Patients With Stroke
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03789357|
Recruitment Status : Recruiting
First Posted : December 28, 2018
Last Update Posted : December 28, 2018
Strokes leads to significant morbidity and mortality, and hypertension is the most important risk factor for strokes. It is estimated that up to 10% of patients with hypertension have the underlying, treatable condition of primary aldosteronism. Hence, we hypothesize that the prevalence of primary aldosteronism is high in patients with strokes, a complication of long-standing hypertension.
Patients admitted with an acute stroke to the Acute Stroke Unit, Changi General Hospital, will be screened for Primary Aldosteronism three months post-stroke, and confirmatory tests will be done with saline-infusion test.
|Condition or disease||Intervention/treatment|
|Primary Aldosteronism Stroke||Diagnostic Test: Aldosterone renin ratio|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Prevalence of Primary Aldosteronism in Patients With Stroke|
|Actual Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||June 30, 2021|
All patients admitted to the Acute Stroke Unit
Diagnostic Test: Aldosterone renin ratio
Aldosterone Renin Ratio to screen for Primary Aldosteronism
- Percentage of patients with stroke with confirmed primary aldosteronism in patients admitted to the acute stroke unit for stroke [ Time Frame: 6 months ]Percentage of patients with confirmed Primary Aldosteronism using confirmatory test
- Accuracy of Screening test in early period post-stroke [ Time Frame: 3 months ]To determine if the screening blood test for primary aldosteronism performed within 1 week post-stroke is equally accurate compared to being performed 2-4 months post-stroke.
- Percentage of unilateral primary aldosteronism in patients admitted with acute stroke [ Time Frame: 6 months ]Percentage of unilateral PA amongst patients with stroke
- Percentage of patients with positive screening test in patients admitted with acute stroke [ Time Frame: 3 months ]
- Blood pressure change after treatment for primary aldosteronism [ Time Frame: 12 months ]
- Cardiac Complications [ Time Frame: 6 months ]Cardiac complications in patients with primary aldosteronism, compared to those without primary aldosteronism, as assessed by transthoracic echocardiography features of left ventricular hypertrophy / mass, and diastolic dysfunction
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789357
|Contact: Troy Puar, MRCP (UK)||firstname.lastname@example.org|
|Changi General Hospital||Recruiting|
|Singapore, Singapore, 529889|
|Contact: Troy H Puar, MRCP UK|
|Principal Investigator: Meifen Zhang, MRCP|
|Principal Investigator:||Troy Puar, MRCP UK||Changi General Hospital|